Abstract Nivolumab is a standard second-line therapy for advanced esophageal squamous cell carcinoma (ESCC), based on pivotal phase III trials largely conducted in Asian populations. Real-world evidence in Western patients remains limited. Systemic inflammation- and nutrition-based indices have been proposed as prognostic biomarkers in immunotherapy but remain scarcely validated in ESCC.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Noemí
Contact Noemí, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack